Vortex Energy Stock Quote VRTX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.065

Bid

0.06

Ask

0.065

Volume

34,267

0.065 Day's Range 0.07

0.065 52 Week Range 0.85

Previous Close

0.065

Open

0.065

Last Trade

2000

0.065

Last Trade Time

Average Volume (3m)

102,640

Financial Volume

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.03	-31.5789473684	0.095	0.095	0.065	234757	0.07485711	CS
4	-0.03	-31.5789473684	0.095	0.105	0.065	120799	0.08514362	CS
12	-0.11	-62.8571428571	0.175	0.175	0.065	102640	0.10746535	CS
26	-0.145	-69.0476190476	0.21	0.27	0.065	75342	0.14521907	CS
52	-0.335	-83.75	0.4	0.85	0.065	154685	0.39379283	CS
156	-0.035	-35	0.1	2.32	0.065	201692	0.94468727	CS
260	-0.035	-35	0.1	2.32	0.065	201692	0.94468727	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TONETriple One Metals Inc	$ 0.015 (200.00%)	1.17M
LANDCumberland Resources Nickel Corp	$ 0.02 (100.00%)	4.48M
CHGXChitogenX Inc	$ 0.01 (100.00%)	50.48k
SOLSOL Global Investments Corp	$ 0.135 (92.86%)	2.44M
HPSSHybrid Power Solutions Inc	$ 0.085 (88.89%)	2.51M
CRIVCarson River Ventures Corp	$ 0.025 (-68.75%)	3.8k
RXMRockex Mining Corporation	$ 0.01 (-50.00%)	12.65k
TGIF1933 Industries Inc	$ 0.005 (-50.00%)	96.97k
AUEXAdvanced Gold Exploration Inc	$ 0.005 (-50.00%)	6.65k
VBNPedro Resources Ltd	$ 0.035 (-41.67%)	22k
LANDCumberland Resources Nickel Corp	$ 0.02 (100.00%)	4.48M
QIMCQuebec Innovative Materials Corp	$ 0.215 (-17.31%)	3.08M
CVGRCity View Green Holdings Inc	$ 0.015 (50.00%)	2.7M
HPSSHybrid Power Solutions Inc	$ 0.085 (88.89%)	2.51M
SOLSOL Global Investments Corp	$ 0.135 (92.86%)	2.44M